Merck & Company, Inc.

Merck Sharp & Dohme Corporation

Schering Corporation

Achillion Pharmaceuticals, Inc.

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Other

Neurogen Corporation

Intervet Inc.

Mochida Pharmaceutical Co., Ltd.

Bial - R&d Investments, S.a.

Intervet International B.v.

Merck Sharp + Dohme Corp.

New York University

University of Colorado

William J Greenlee

Arthur A Patchett

Prasun K Chakravarty

Andrew William Stamford

Thomas F Walsh

Zhaoning Zhu

Samuel Chackalamannil

Brian Alexander McKittrick

Nathan B Mantlo

Avinash S Phadke

Jason Allan Wiles

Milind Deshpande

Dawei Chen

Xiangzhu Wang

Akihiro Hashimoto

Venkat Rao Gadhachanda

Qiuping Wang

Godwin Pais

Atul Agarwal

Yan Xia

Tao Guo

Malcolm MacCoss

Jared N Cumming

Corey Strickland

Ulrich Iserloh

Craig D Boyle

Yusheng Wu

Lingyan Wang

Elizabeth M Smith

Suresh D Babu

Wallace T Ashton

Robert D Mazzola, Jr

Johannes H Voigt

Xianhai Huang

Duane A Burnett

Michael W Miller

Ying Huang

Linda L Chang

Anandan Palani

Dooseop Kim

Guoqing Li

Bernard R Neustadt

Hubert B Josien

Renato T Skerlj

Eric J Gilbert

Tin-Yau Chan

David G Hangauer

Peter T Lansbury

Elyse Marie Josee Bourque

Santhosh Francis Neelamkavil

William H Parsons

John W Clader

Jack D Scott

Duane E DeMong

Andrew Charles Good

Michael P Dwyer

James M Balkovec

Wen-Lian Wu

David B Johnston

Liangqin Guo

Deen Tulshian

James R Tata

Dmitri A Pissarnitski

Hongmei Li

Eugene D Thorsett

Sander G Mills

Lihu Yang

Robert G Aslanian

Ann E Weber

Conrad P Dorn

Wenxue Wu

Theodros Asberom

Jay Weinstein

Joseph A Kozlowski

Tesfaye Biftu

Sundeep Dugar

Daniel F Veber

Clarence S Rooney

Theresa M Williams

Walfred S Saari

William C Lumma, Jr

Stuart W McCombie

Barbara A Pio

Wensheng Yu

John S Wai

Joseph Michael Kelly

Xing Dai

Peter D Williams

Zhicai Wu

Malcolm Maccoss

Jan William Wasley

Brian J Lavey

Philip E Sanderson

Zhuyan Guo

William R Schoen

Helen Y Chen

Jing Su

Harry R Chobanian

Derun Li

Joel R Huff

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I'″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma-associated oncogene (Gli) expression. More particularly, this disclosure relates to bicyclic compounds and pharmaceutical compositions thereof, methods of inhibiting Gli expression with these compounds, and methods of treating diseases related to Gli expression.

Inhibitors of GLI1 as therapeutic agents

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Pharmaceutical compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.

Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I&#x2033; and I'&#x2033; or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Amide compounds for treatment of immune and inflammatory disorders

Amino compounds for treatment of immune and inflammatory disorders

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.

Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders

The invention provides substituted pyrrolo[1,2-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-pyrrolo[1,2-a]pyrimidine-8-carboxarnide compounds and variants thereof.

Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders

Growing community of inventors

Teaneck, NJ, United States of America

William J Greenlee